Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Observer-Blind, Placebo-Controlled Study to Assess the Safety, Reactogenicity, and Immunogenicity of the SARS CoV-2 Vaccine ARCT-021 in Healthy Adult Participants

NCT04668339 is registered in ClinicalTrials.gov with Arcturus Therapeutics, Inc. as lead sponsor.

NCT NCT04668339
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04668339 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Observer-Blind, Placebo-Controlled Study to Assess the Safety, Reactogenicity, and Immunogenicity of the SARS CoV-2 Vaccine ARCT-021 in Healthy Adult Participants
Lead sponsor
Arcturus Therapeutics, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
January 7, 2021
Completion date
March 1, 2022
Enrollment
581 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

corona virus infection, covid19, sars-cov infection